32 oasmia

SEB CONFERENCE

F.R. Martelet, M.D., CEO

19 January 2021

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever.

Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.



Oasmia – an innovation-focused specialty pharmaceutical company





XR-17™ technology platform

Enhances intravenous delivery of established and novel drugs in diseases including cancer



Significant in-/out-licensing & M&A opportunities to drive growth



Growing pipeline, focused on

\$698m

Oncology and with potential in other therapeutic areas



Lean and agileSolid cash position



Global partnering deal for Apealea® in ovarian cancer worth up to



Clear new strategy driven by new leadership team



Building the right team for success





FRANCOIS MARTELET,
M.D., Master's Degree Business
Chief Executive Officer



FREDRIK JÄRRSTEN* *Chief Finance Officer*



REINHARD KOENIG, M.D.Acting Chief Medical Officer



ELIN TRAMPE, M.A. *Chief Technical Officer*



PETER SELIN B.Sc. *Chief Business Officer*



ANDERS HÄRFSTRAND, M.D., PhD. Non-executive Chairman



HEGE HELLSTRÖM, B.A. *Board Member*




PETER ZONABEND, LL.M, EMLE Board Member



BIRGIT STATTIN
NORINDER, M.Sc.
Board Member



2020 – a year of delivering and transformation







XR-17[™] – tackling poor drug solubility

POOR API¹ SOLUBILITY

Major challenge in drug development

Critical to drug bioavailability

AFFECTS c.40% OF APPROVED DRUGS²

70-90% of pipeline drugs classed as poorly soluble²

Leading cause of project termination

IMPLICATED IN SERIOUS
ADVERSE EVENTS

Solubility enhancers can cause SAEs and / or require use of further drugs

Accepted trade off in cancer therapy

A SIGNIFICANT PROBLEM FOR PATIENTS AND PHARMA COMPANIES

\$180 bn SPENT ON PHARMA R&D EVERY YEAR ³

69%
OF DRUGS
FAIL DUE TO
LOW
SOLUBILITY ³


L) API = Active Pharmaceutical Ingredient - the ingredient in a pharmaceutical drug that is biologically active

²⁾ Nikolakakis & Partheniadis

¹⁾ NIKUIAKAKIS & PAITIIEI




XR-17[™] – potentially improving safety and efficacy



Building a portfolio, focused initially on cancer





Apealea® – offering an improved treatment option in ovarian cancer











Genexol-PM® Korea

Solvent-free IV formulation of paclitaxel

- No polyoxyethylated castor oil or dehydrated alcohol
- No glucocorticosteroids required premedication
- Shorter infusion and overall 'chair' time

Approved in EU for treatment of first relapse ovarian cancer¹

Targeting patients unable to tolerate solvent-based paclitaxel

Company	🂸 oasmia	ullı Bristol Myers Squibb	Celgene	LUYE PHARMA	*samyang** Biopharm
Indication	Ovarian Cancer	Ovarian Cancer Breast Cancer NSCLC	Breast Cancer	Ovarian Cancer Breast Cancer NSCLC	Ovarian Cancer Breast Cancer NSCLC
Infusion Solution	Micellar Solution	Emulsion	Colloidal Suspension	Liposome	Micellar Solution
Particle Size	25nm	10-22nm	130nm	400nm	~25nm
Excipient	XR-17™	Cremophor EL	Human Albumin	Lecithin/Cholesterol	PEG-PDLLA
Dose	250mg/m ²	175mg/m²	260mg/m ²	175mg/m²	260mg/m ²
Ratio (Excipient : API)	1.3:1.0	88.0:1.0	9.0:1.0		5.0:1.0
Infusion Time	1h	3h	<1h	3h	0.5h
Pre-medication	Not mandatory	Yes	No	Yes	No
Hypersensitivity	No	Yes	No	Yes	No





Apealea® – global partnership worth up to \$698m + royalties



Agreement with US-based Elevar Therapeutics, subsidiary of South Korea's HLB

%


Double digit royalties on global Apealea® sales

\$678M

Milestones based on regulatory and sales achievements



Oasmia retains sole control over development of XR-17™ in other APIs











Oasmia commercializing





USA

Pathway to commercialization identified and being executed by Elevar

Europe (excluding Nordics)


INCEPTUA

Commercialization agreement signed between Elevar Therapeutics and Inceptua Group



Middle East and North Africa (MENA)

Commercialization agreement signed between Elevar Therapeutics and Taiba Middle East FZ LLC



Asia

Discussions with potential partners progressing well



Global

 Named patient program launched by Tanner Pharma ex US

LatAm

Discussions with potential partners progressing well






Docetaxel micellar – initiating phase 1b to target prostate cancer


- Docetaxel approved for wide range of solid malignancies
- Standard of care for advanced prostate cancer
- Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel without solubility enhancers
- SAKK (Swiss Group for Clinical Cancer Research) to initiate Phase Ib trial early 2021





Improving and expanding the use of our technologies







Focusing resources – strong cash position & reduced burn rate

	2019/20	2019	2020
	May - Apr	May - Jul	May - Jul
Cash and Cash equivalents, TSEK*	435,000	109,000	354,000
Number of shares at the end of the period, before and after dilution, in thousands ¹	448,370	326,313	448,370
Weighted average number of shares, before and after dilution, in thousands ¹	398,395	303,577	448,370
Earnings per share, before and after dilution, SEK ^{1,2}	-0.03	-0.13	-0.12
Equity per share, SEK ^{1,3}	1.83	1.28	1.71
Equity/assets ratio, % ⁴	82	63	82
Net debt, TSEK	neg.	32,001	neg.
Net debt/equity ratio, % ⁵	neg.	8	neg.
Return on total assets, %	neg.	neg.	neg.
Return on equity, %	neg.	neg.	neg.
Number of employees at the end of the period	63	55	59

^{*} Includes short term investments



¹⁾ The key figures for the comparison periods have been adjusted for the bonus issue component in the rights issue carried out in 2019/2020.

²⁾ The figures for the first quarter of 2019 have been restated after error correction for 2019/2020 compared with the interim report on July 31, 2019, in which the amount was SEK -0.17.

³⁾ The figures for the first quarter of 2019 have been restated after error correction for 2019/2020 compared with the interim report on July 31, 2019, in which the amount was SEK 1.72..

Looking ahead – multiple catalysts and investment drivers



Potential near and mid-term value drivers

- Elevar partnering for Apealea® in key territories and milestone payments and royalties
- SAKK docetaxel micellar Phase Ib initiation
- New XR-17™ oncology API to be disclosed
- M&A and in-licensing opportunities to build critical mass in oncology/spec pharma
- Partnering of XR-17[™] and animal health assets
- XR-18 platform development and XR-19 lab proof of concept

Investment drivers

- Commercial-stage company with proven capabilities
- Validated XR-17[™] technology platform with potential for expansion
- Growing oncology pipeline targeting large global markets
- Transformational global partnership
- Strong cash position
- Positioned for strong growth

Our four-pillar strategy for growth



1

Execute on
Apealea® global
partnership with
Elevar Therapeutics

2

Partnering & clinical development with XR-17™ / XR-19 platforms

3

Clinical development of Docetaxel micellar and new API(s)

4

In / out-licensing, partnering & M&A in oncology

S oasmla Thank you!

Oasmia Pharmaceutical AB (STO: OASM)

Vallongatan 1 752 28 Uppsala Sweden



+46 018-50 54 40



IR@oasmia.com



www.oasmia.com



www.linkedin.com/comp any/oasmiapharmaceutical-ab



www.twitter.com/Oasmia